Aduro Biotech Gets Two U.S. Patents

Aduro Biotech said Wednesday that it has received two patents from the United States Patent and Trademark Office related to the activation of the STING Pathway.

The company received U.S. patent 9,724,408, which is jointly owned with the University of California, covers ADU-S100, an investigational STING pathway activator; and patent 9,695,212, which covers claims methods of using certain additional cyclic dinucleotides to induce STING-dependent immune responses. Shares were 1% lower in midday trade.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Comment